

Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015

<https://marketpublishers.com/r/T13A069F20CEN.html>

Date: April 2015

Pages: 1200

Price: US\$ 2,400.00 (Single User License)

ID: T13A069F20CEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for phosphorylation. It has been found that mutation or other anomaly in these enzymes causes uncontrolled cell division leading to cancer. Because of their direct involvement in cell division they are used in cancer treatment by using kinase inhibitors to prevent unregulated cellular proliferation. Epidermal Growth Factor Receptor Family (EGFR) are present on the cell surface and anomalies like mutations leads to the cancer formation and its members have been found to have activity like receptor tyrosine kinases. EGFR Members of these families have been found to be overexpressed in various malignancies like breast cancer, glioblastoma and lung cancer. They are utilized for formulating targeted therapeutics for cancer treatment. Her1/ Her2 are commonly found to be overexpressed in case of breast cancer and many cancer therapeutics have been developed to treat metastatic condition.

Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at various phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. As a result, several products are at different stages of clinical trials which will be introduced in market in coming years. Some tyrosine kinase medical care products including mAbs are costly to produce but large patient base and superior pharmacological benefits are some factors responsible for continuous growth of this market segment. Development and discovery of innovative technologies for commercialization is increasing because of large financial inputs. As a result, more therapeutic options will be available to patients at cost effective rates. Their disease coverage is increasing continuously due to which their market penetration is expected to increase several folds in coming years.

Increasing disease incidences especially cancer has attracted several pharmaceutical companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first of this kind to enter in global market. Targeted therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine kinase inhibitors are expected to increase in coming years. Small molecule based targeted therapeutics will offer competition to monoclonal antibodies in terms of pharmacological efficacy but pricing and commercialization strategies are also expected to play a major role.

Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy profiles along with minimized side effects. Several mAbs binding to different tyrosine receptors have been formulated by pharmaceutical companies generating significant revenues across the globe. For instance, Genentech's trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor kinase due to which severe competition would be found in certain categories. EGFR is widely studied due to which majority of tyrosine kinase therapeutics belong to this category. Moreover, it is involved in breast cancer which has well developed market so revenues generated by this segment are expected to be significantly higher than other cancer categories.

Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive product are expected to enter continuously in global market. Owing to increasing disease incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic.

'Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015' Report Highlight:

Global Tyrosine Kinase Therapeutics Market Overview

Mechanism of Tyrosine Kinase Therapeutics

Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase

Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs

Majority Drugs in Preclinical Phase: 239 Drugs

Marketed Tyrosine Kinase Inhibitors: 58 Drugs

Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication

Contents

1. INTRODUCTION TO TYROSINE KINASES INHIBITORS

2. MECHANISM OF TYROSINE KINASE THERAPEUTICS

3. GLOBAL TYROSINE KINASE THERAPEUTICS MARKET OVERVIEW

3.1 Current Market Scenario

3.2 Tyrosine Kinase Inhibitors Pipeline Overview

4. GLOBAL TYROSINE KINASE THERAPEUTICS MARKET DYNAMICS

4.1 Favorable Market Parameters

4.2 Market Challenges

5. GLOBAL TYROSINE KINASE THERAPEUTICS MARKET FUTURE PROSPECTS

6. GLOBAL TYROSINE KINASE INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

6.1 Unknown

6.2 Research

6.3 Preclinical

6.4 Clinical

6.5 Phase-I

6.6 Phase-I/II

6.7 Phase-II

6.8 Phase-II/III

6.9 Phase-III

6.10 Preregistration

6.11 Registered

7. MARKETED TYROSINE KINASE INHIBITORS BY COMPANY & INDICATION

8. SUSPENDED & NO DEVELOPMENT REPORTED TYROSINE KINASE INHIBITORS PIPELINE

8.1 No Development Reported

8.2 Discontinued

8.3 Market Withdrawal

8.4 Suspended

9. COMPETITIVE LANDSCAPE

9.1 Advenchen Laboratories

9.2 Array Pharmaceuticals

9.3 AstraZeneca

9.4 Bayer Healthcare Pharmaceuticals

9.5 Biogen Idec

9.6 Bristol-Myer Squibb

9.7 Boehringer Ingelheim

9.8 Chugai Pharmaceutical

9.9 Celgene Corporation

9.10 Exelixis

9.11 Incyte Corporation

9.12 GalaxoSmithKline

9.13 Johnson & Johnson

9.14 Merck

9.15 Novartis

9.16 Onyx pharmaceuticals

9.17 Pfizer

9.18 Sanofi

9.19 Tolero Pharmaceutical

9.20 QIAGEN

List Of Figures

LIST OF FIGURES

- Figure 1-1: Flow Chart of Phosphorylation
- Figure 1-2: Hierarchy of EFGR Family
- Figure 1-3: Hierarchy of VEGFR Family
- Figure 1-4: Features of Receptor Tyrosine Kinase
- Figure 1-5: Benefits of Tyrosine Kinase Inhibitors
- Figure 2-1: Properties of Tyrosine Kinase Therapeutics
- Figure 2-2: Mechanism of Nexavar
- Figure 2-3: Mechanism of Gleevac
- Figure 2-4: Mechanism of Tyverb
- Figure 2-5: Benefits of Monoclonal Antibodies
- Figure 2-6: Mechanism of Avastin
- Figure 2-7: Mechanism of Rituximab
- Figure 3-1: Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
- Figure 3-2: Tyrosine Kinase Inhibitors Pipeline by Phase (Numbers), 2015
- Figure 3-3: No Development Reported in Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
- Figure 3-4: No Development Reported in Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
- Figure 3-5: Discontinued Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
- Figure 3-6: Discontinued Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
- Figure 3-7: Suspended Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
- Figure 3-8: Suspended Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
- Figure 4-1: Tyrosine Kinase Therapeutics Favorable Market Parameters

COMPANIES

Advenchen Laboratories, Array Pharmaceuticals, AstraZeneca, Bayer Healthcare Pharmaceuticals, Biogen Idec, Bristol-Myer Squibb, Boehringer Ingelheim, Chugai Pharmaceutical, Celgene Corporation, Exelixis, Incyte Corporation, GalaxoSmithKline, Johnson & Johnson, Merck, Novartis, Onyx pharmaceuticals, Pfizer, Sanofi, Tolero Pharmaceutical, QIAGEN

I would like to order

Product name: Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015

Product link: <https://marketpublishers.com/r/T13A069F20CEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T13A069F20CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970